PHOENIX SNOWBALL WORST-OF - MODERNA/EXELIXIS/VERTEX PHARMACEUTICALS PHOENIX SNOWBALL WORST-OF - MODERNA/EXELIXIS/VERTEX PHARMACEUTICALS Share Price
Certificat
P1NZ89
NLBNPIT1NZ89
| Market Closed - Borsa Italiana 09:14:59 17/05/2024 pm IST | ||
| 93.99 EUR | +0.38% |
|
| Current month | +4.79% | ||
| 1 month | +7.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 93.99 | +0.38% |
| 16/24/16 | 93.63 | +0.69% |
| 15/24/15 | 92.99 | -0.75% |
| 14/24/14 | 93.69 | +1.12% |
| 13/24/13 | 92.65 | +0.77% |
Real-time Borsa Italiana
Last update May 17, 2024 at 09:14 pm IST
More quotesStatic data
| Product type | sonstige Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
BNP Paribas
|
| P1NZ89 | |
| ISIN | NLBNPIT1NZ89 |
| Date issued | 22/03/2023 |
| Maturity | 20/03/2026 (672 Days) |
| Parity | 1 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 101 € |
|---|---|
| Lowest since issue | 67.62 € |
| Spread | 1 € |
| Spread % | 1.06% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Certificates
- P1NZ89 Certificat